These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23465046)

  • 1. Environmental prevention of infection in stem cell transplant recipients: a survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Hicheri Y; Einsele H; Martino R; Cesaro S; Ljungman P; Cordonnier C
    Transpl Infect Dis; 2013 Jun; 15(3):251-8. PubMed ID: 23465046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European group for blood and marrow transplantation.
    Krüger WH; Hornung RJ; Hertenstein B; Kern WV; Kröger N; Ljungman P; Zander AR;
    J Hematother Stem Cell Res; 2001 Dec; 10(6):895-903. PubMed ID: 11798516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey.
    Rasheed W; Ghavamzadeh A; Hamladji R; Ben Othman T; Alseraihy A; Abdel-Rahman F; Elhaddad A; Alabdulaaly A; Dennison D; Ibrahim A; Bazarbachi A; Bekadja MA; Mohamed SY; Adil SN; Ahmed P; Benchekroun S; Ramzi M; Jarrar M; Alimoghaddam K; Hussain F; Hamidieh A; Aljurf M
    Hematol Oncol Stem Cell Ther; 2013 Mar; 6(1):14-9. PubMed ID: 23664600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study.
    Vokurka S; Bystrická E; Svoboda T; Škoda Gorican IK; Sever M; Mazur E; Kopinska A; Pavlicová V; Mocanu O; Tanase A; Ghelase R; Zítková M; Labudíková M; Raida L; Hrabánková-Navrátilová D; Bocková J
    J Clin Nurs; 2014 Jun; 23(11-12):1648-52. PubMed ID: 24354726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation.
    Rizzo JD; Wingard JR; Tichelli A; Lee SJ; Van Lint MT; Burns LJ; Davies SM; Ferrara JL; Socié G
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):138-51. PubMed ID: 16443512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT.
    Ljungman P; Engelhard D; de la Cámara R; Einsele H; Locasciulli A; Martino R; Ribaud P; Ward K; Cordonnier C;
    Bone Marrow Transplant; 2005 Apr; 35(8):737-46. PubMed ID: 15750612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation for non-Hodgkin lymphoma.
    Nademanee A
    Expert Rev Hematol; 2009 Aug; 2(4):425-42. PubMed ID: 21082947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective environment for hematopoietic cell transplant (HSCT) recipients: The Infectious Diseases Working Party EBMT analysis of global recommendations on health-care facilities.
    Styczynski J; Tridello G; Donnelly JP; Iacobelli S; Hoek J; Mikulska M; Aljurf M; Gil L; Cesaro S
    Bone Marrow Transplant; 2018 Sep; 53(9):1131-1138. PubMed ID: 29535381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
    Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
    Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT).
    Bejanyan N; Bolwell BJ; Lazaryan A; Rybicki L; Tench S; Duong H; Andresen S; Sobecks R; Dean R; Pohlman B; Kalaycio M; Copelan EA
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):874-80. PubMed ID: 22040844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers.
    Bourassa-Blanchette S; Knoll G; Tay J; Bredeson C; Cameron DW; Cowan J
    Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28423227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation activities and treatment strategies in paediatric stem cell transplantation centres: a report from the EBMT Working Party on Paediatric Diseases. European Group for Blood and Marrow Transplantation.
    Peters C; Ladenstein R; Minkov M; Pötschger U; Gadner H; Cornish J; Dini G; Klingebiel T; Locatelli F; Vossen J; Niethammer D
    Bone Marrow Transplant; 1998 Sep; 22(5):431-7. PubMed ID: 9733265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations.
    Fraser GA; Walker II;
    Biol Blood Marrow Transplant; 2004 May; 10(5):287-97. PubMed ID: 15111928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.